News | RIVM

Lyme disease costs EUR 20 million annually

The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.

EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention

RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.

Lab tests alone not conclusive for diagnosis of Lyme disease

Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.

RIVM recommends more stringent EU standards BPA

More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.

Major loss of healthy life years due to long-term complaints after Lyme disease

The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.

Biobased alternatives to hormone disrupting substance in cash register receipts

Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.

RIVM provides overview of the possible risks of bisphenol A

RIVM has created an overview of the possible risks of Bisphenol A (BPA) for humans and the environment. BPA is a component of many different products and affects the endocrine system.